As of Thursday close, Eli Lilly and Company’s (NYSE:LLY) stock was down -$5.32, moving down -1.17 percent to $449.16. The average number of shares traded per day over the past five days has been 2,013,880 shares. 2 times new highs have been achieved over the past 5 days, with a -$5.83 fall in that time frame. In the last twenty days, the average volume was 2,345,945, while in the previous 50 days, it was 2,590,510.
Since last month, LLY stock retreated -3.55%. Shares of the company fell to $434.34 on 07/13/23, the lowest level in the past month. A 52-week high of $469.87 was reached on 06/30/23 after having rallying from a 52-week low of $296.32. Since the beginning of this year, LLY’s stock price has risen by 22.77% or $83.32, and marked a new high 26 times. However, the stock has declined by -4.41% since its 52-week high.
LLY stock investors should be aware that Eli Lilly and Company (LLY) stock had its last reported insider trading activity 14 days ago on Jul 21. LILLY ENDOWMENT INC, the 10% Owner of the company, disposed of 591 shares for $466.62 on Jul 21. It resulted in a $275,773 divestment by the insider. LILLY ENDOWMENT INC sold 164,125 shares at an average price of $467.60 on Jun 30. The insider now owns 101,028,810 shares following the transaction. On Jun 29, 10% Owner LILLY ENDOWMENT INC sold 44,115 shares at $465.08 apiece. The transaction was valued at $20,517,137.
Valuation Metrics
Right now, Eli Lilly and Company (LLY) has a P/E ratio of about 71.31. The stock’s beta is 0.35. Besides these, the trailing price-to-sales (P/S) ratio of 15.28, the price-to-book (PB) ratio of 36.16, and the price-to-cash flow ratio of 3585.86 may also be considered.
The latest dividend of $1.13 per share was paid out, remained unchanged from last year’s $1.13.
Financial Health
In the three months ended March 30, Eli Lilly and Company’s quick ratio stood at 1.00, while its current ratio was 1.30, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 1.69, and the total debt-to-equity ratio was 1.69. On the profitability front, the trailing twelve-month gross margin is 77.70% percent. In the year ended March 30, EBITDA margin amounted to 34.35%, whereas operating margins totaled 22.50%. Based on annual data, LLY earned $21.91 billion in gross profit and brought in $28.54 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 24.40%. Return on equity (ROE) for the past 12 months was 56.20%.
In Eli Lilly and Company’s quarter-end financial report for March 30, it reported total debt of $18.88 billion against cash and short-term investments of $123.4 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. LLY’s revenue fell -12.21% to $7.3 billion during the quarter, while net income inched up to $6.96 billion. While analysts expected Eli Lilly and Company to report $1.73 quarterly earnings, the actual figure was $1.62 per share, beating the consensus estimate by -6.40%. During the quarter, the company generated $1.86 billion in EBITDA. The liabilities of Eli Lilly and Company were 41.87 billion at the end of its most recent quarter ended March 30, and its total debt was $18.99 billion. The value of shareholders’ equity is $949.27 million.
Technical Picture
This quick technical analysis looks at Eli Lilly and Company’s (LLY) price momentum. With a historical volatility rate of 9.36%, the RSI 9-day stood at 42.20% on 03 August.
With respect to its five-day moving average, the current Eli Lilly and Company price is down by -1.28% percent or -$5.83. At present, LLY shares trade -3.03% below its 20-day simple moving average and +42.58% percent above its 100-day simple moving average. However, the stock is currently trading approximately +3.50% above its SMA50 and +35.54% above its SMA200.
Stochastic coefficient K was 44.72% and Stochastic coefficient D was 55.36%, while ATR was 8.11. Given the Stochastic reading of 24.81% for the 14-day period, the RSI (14) reading has been calculated as 46.89%. As of today, the MACD Oscillator reading stands at -2.78, while the 14-day reading stands at -2.97.
Analyst Ratings
Citigroup reiterated its a Buy rating on Eli Lilly and Company (NYSE: LLY) in a note to investors. The analysts firm has however raised their price target to $525, representing a possible -24.77% increase in the stock price. Eli Lilly and Company (LLY) has been rated Overweight by analysts. According to 1 brokerage firm, LLY is a sell, and 7 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 2 analysts rate Eli Lilly and Company stock as buy, with 19 recommending it as overweight.
With a median target price of $500.00, the current consensus forecast for the stock is $300.00 – $565.00. Based on these forecasts, analysts predict Eli Lilly and Company (LLY) will achieve an average price target of $479.49.
